Want to see IGC full AI Analyst Report?
Top Page
IGC Pharma
(IGC)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.30
▲(13.85% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance (very small revenue, steep losses, and ongoing cash burn). Technicals are somewhat supportive with price above major moving averages, but overbought signals temper the outlook. Valuation is constrained by negative earnings and no stated dividend, while recent corporate events provide only a modest balance-sheet/financing benefit.
Positive Factors
Phase 2 trial nearing enrollment completion
Near-complete enrollment moves IGC-AD1 toward database lock and topline analysis, creating a defined milestone for regulatory and strategic evaluation. A completed dataset can clarify efficacy and development potential, although approval is not assured.
Negative Factors
Small and declining revenue base
Minimal and declining revenue indicates that IGC has not yet established a meaningful commercial foundation. The company remains dependent on clinical success and external financing rather than internally generated sales to support operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 trial nearing enrollment completion
Near-complete enrollment moves IGC-AD1 toward database lock and topline analysis, creating a defined milestone for regulatory and strategic evaluation. A completed dataset can clarify efficacy and development potential, although approval is not assured.
Read all positive factors
IGC Pharma (IGC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.81M
Dividend YieldN/A
Average Volume (3M)715.71K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding103,384,010
10 Day Avg. Volume826,885
30 Day Avg. Volume715,709
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.08
Price to Sales (P/S)21.08
P/FCF Ratio-4.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.50Price Target Upside2015.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$1.10M
IGC Pharma Business Overview & Revenue Model
Company Description
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates a...
How the Company Makes Money
null...
IGC Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.12M | 1.19M | 1.27M | 1.34M | 911.00K | 397.00K |
| Gross Profit | 246.00K | 352.00K | 619.00K | 733.00K | -158.00K | 194.00K |
| EBITDA | -7.44M | -6.22M | -6.66M | -12.36M | -10.85M | -14.37M |
| Net Income | -7.88M | -6.55M | -7.12M | -13.00M | -11.51M | -15.02M |
Balance Sheet | ||||||
| Total Assets | 9.50M | 9.19M | 8.75M | 9.90M | 17.18M | 26.83M |
| Cash, Cash Equivalents and Short-Term Investments | 354.00K | 235.00K | 405.00K | 1.20M | 3.35M | 10.46M |
| Total Debt | 1.08M | 926.00K | 241.00K | 348.00K | 481.00K | 611.00K |
| Total Liabilities | 3.36M | 3.06M | 2.42M | 2.58M | 2.27M | 2.94M |
| Stockholders Equity | 6.13M | 6.12M | 6.33M | 7.32M | 14.91M | 23.89M |
Cash Flow | ||||||
| Free Cash Flow | -3.35M | -6.11M | -5.28M | -5.71M | -7.67M | -8.23M |
| Operating Cash Flow | -3.31M | -5.94M | -4.79M | -5.20M | -7.05M | -7.46M |
| Investing Cash Flow | -1.03M | -192.00K | -442.00K | -317.00K | -235.00K | -742.00K |
| Financing Cash Flow | 6.81M | 5.93M | 4.45M | 3.52M | 100.00K | 4.14M |
IGC Pharma Technical Analysis
Neutral
0.26
Price Trends
0.27
Positive
0.28
Negative
0.29
Negative
Market Momentum
<0.01
Negative
55.92
Neutral
82.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Neutral. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.27, and below the 200-day MA of 0.29, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.92 is Neutral, neither overbought nor oversold. The STOCH value of 82.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IGC.
IGC Pharma Risk Analysis
IGC Pharma disclosed 37 risk factors in its most recent earnings report. IGC Pharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IGC Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $29.81M | -3.40 | -94.51% | ― | ― | ― | |
48 Neutral | $41.60M | 0.74 | 940.81% | ― | -48.76% | -3.02% | |
47 Neutral | $85.38M | -2.81 | -444.44% | ― | 106.21% | 79.84% | |
42 Neutral | $28.24M | -3.66 | -2918.10% | ― | -8.05% | -14.12% | |
40 Underperform | $17.26M | -0.56 | 203.55% | ― | 4.35% | 20.37% |
* Healthcare Sector Average
IGC
IGC Pharma
0.28
-0.09
-24.53%
PLUR
Pluri
1.60
-2.91
-64.52%
DYAI
Dyadic International
0.78
-0.01
-1.27%
VRCA
Verrica Pharmaceuticals
4.89
-1.16
-19.17%
ELUT
Elutia
0.98
-1.05
-51.73%
IGC Pharma Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
IGC Pharma Executives Convert Debt Into Equity Shares
Positive
Jul 6, 2026
On June 30, 2026, IGC Pharma’s CEO Ram Mukunda and Vice President and Principal Financial Officer Claudia Grimaldi converted a combined $1.15 million of outstanding obligations, including several years of personal cash advances, into newly i...
Business Operations and StrategyPrivate Placements and Financing
IGC Pharma Extends and Amends $12 Million Loan Facility
Positive
Jun 8, 2026
IGC Pharma, Inc. amended and extended its existing Master Loan and Security Agreement and General Banking Facility Letter with Taiwan-based O-Bank Co., Ltd. on June 5, 2026. The renewed facility maintains a maximum aggregate limit of $12,000,000 w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.